Am Fam Physician. 1998 Mar 15;57(6):1238-1239.
to the editor: I wish to expand on several points in a recent article on reducing the complications in type 2 (non-insulin–dependent) diabetes.1 The authors cite the results of the Diabetes Control and Complications Trial (DCCT), which studied glycemic control in patients with type 1 (insulin-dependent) diabetes, and discuss its implications for patients with type 2 diabetes. However, there is now a similar study of glycemic control performed in patients with type 2 diabetes that is more relevent to other patients with type 2 diabetes.2 The study randomized 110 patients with type 2 diabetes to intensive or conventional insulin treatment for six years and found reductions in nephropathy, retinopathy and neuropathy that were similar to those found in the DCCT.2 The glycemic threshold to prevent these complications was a hemoglobin A1c level less than 6.5 percent.
Though glycemic control is important, the importance of blood pressure control, at least in the prevention of diabetic nephropathy, cannot be overemphasized. The goal for patients with type 2 diabetes is to maintain a blood pressure less than 130/85 mm Hg, with further reductions as tolerated.3 Angiotensin-converting enzyme (ACE) inhibitors are recommended as first-line therapy for antihypertensive treatment, since they lower glomerular capillary pressure and preserve glomerular filtration rate more than can be explained by their blood pressure effects alone.4
In one important ACE inhibitor study, Ravid and colleagues5 randomized 94 patients with type 2 diabetes who were normotensive and had normal renal function and microalbuminuria to enalapril maleate (Vasotec), in a dosage of 10 mg per day or placebo, and followed them over five years. While the enalapril group's average protein excretion remained stable at approximately 140 mg per 24 hours, the placebo group's protein excretions increased from 123 to 310 mg per 24 hours.5 The American Diabetes Association (ADA) supports the use of ACE inhibitors when type 2 diabetes is accompanied by microalbuminuria and normal blood pressure; for those who have progressed from microalbuminuria to proteinuria, the ADA also recommends dietary protein reductions to 0.8 g per kg per day or 10 percent of calories.3
The recent lowering of the fasting blood glucose cutoff for diagnosing diabetes to 126 mg per dL (6.9 mmol per L)6 or greater should allow for earlier diagnosis of diabetes and more effective secondary prevention of complications. Recently, the NIH has launched a multicenter primary prevention trial, the Diabetes Prevention Program (DPP), to find the best way to prevent type 2 diabetes. Successful primary prevention could be the most effective method yet of reducing the microvascular complications of diabetes. While we await the results of the DPP, efforts should be focused on the screening of high risk individuals with fasting blood sugars, the aggressive control of blood pressure and blood sugar and the appropriate use of ACE inhibitors in patients with type 2 diabetes.
1. Susman JL, Helseth LD. Reducing the complications of type II diabetes: a patient-centered approach. Am Fam Physician. 1997;56:471–80.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents to progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
3. American Diabetes Association: Clinical Practice Recommendations 1996. Diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care. 1996;19(Suppl 1):S103–6.
4. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129–38.
5. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81.
6. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–97.
in reply: We appreciate Dr. Poirier's comments on our article and wish to briefly clarify several important points. Ohkubo and colleagues1 do provide significant additional evidence for our assertion that microvascular complications in type 2 diabetes are linked to hyperglycemia. However, this study is limited by the small sample size (110 patients) and the inclusion of only nonobese, Japanese, insulin-treated patients. This study also fails to resolve the question of the effects of tighter glycemic control using insulin on macrovascular complications.
We do agree with Dr. Poirier's emphasis on the importance of controlling blood pressure and preventing nephropathy. Nonetheless, we continue to believe that a patient-centered approach may necessitate trade-offs between ideal biomedical management and patient preferences. As Dr. Poirier suggests, the lowering of the fasting blood glucose cutoff for diagnosing diabetes to 126 mg per dL (6.9 mmol per L) or greater will provide an opportunity to diagnose diabetes earlier.2 We hope physicians can use this extra lead time to educate their patients, to gain a better understanding of their priorities and to facilitate negotiation of mutually agreed upon goals for management.
1. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–97.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions